Histogenics Corporation Selects ImageIQ to Provide Imaging Analysis for Phase 3 Clinical Trial

Published: Jul 26, 2012

CLEVELAND--(BUSINESS WIRE)--ImageIQ, a Cleveland Clinic-founded contract research organization providing imaging analysis software and services, announces that it has been chosen by Histogenics, a regenerative medicine company, to provide imaging analytics for the Phase 3 IND clinical trial of the company’s NeoCart implant. NeoCart is an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions.

Back to news